MOLMED

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed’s pipeline includes antitumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, currently in Phase III in high-risk acute leukaemia and under evaluation by EMA for a Conditional Marketing Auth... orization; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the tumour mass, currently investigated in a broad clinical programme; CAR-CD44v6, an immuno-gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also conducts cell and gene therapy projects in collaboration with third parties, offering resources and expertise covering preclinical to Phase III trials activities.

#SimilarOrganizations #People #Financial #Website #More

MOLMED

Social Links:

Industry:

Biotechnology

Founded:

1996-01-01

Address:

Bresso, Lombardia, Italy

Country:

Italy

Website Url:

http://www.molmed.com

Total Employee:

101+

Status:

Active

Contact:

+39 0221277.1

Email Addresses:

[email protected]

Total Funding:

15 M EUR

Technology used in webpage:

GoDaddy SSL Apple Whitelist

Similar Organizations

faze-medicines-logo

Current Employees Featured

riccardo-palmisano_image

Riccardo Palmisano
Riccardo Palmisano CEO & Co-Founder @ MolMed
CEO & Co-Founder
2015-11-01

Founder

riccardo-palmisano_image

Riccardo Palmisano

Investors List

european-investment-bank_image

European Investment Bank

European Investment Bank investment in Debt Financing - MolMed

Official Site Inspections

http://www.molmed.com

Host Informations
Whois Informations

Loading ...